![]() |
市場調查報告書
商品編碼
1422065
全球原位雜交市場:按產品類型,技術,探針類型,應用,最終用戶,地區,機會,預測2017-2031 年In situ Hybridization Market Assessment, By Product Type, By Technology, By Probe Type, By Application, By End-Users, By Region, Opportunities and Forecast, 2017-2031F |
2023年全球原位雜交市場規模達16.4億美元。預計到 2031 年,市場規模將達到 35.3 億美元,2024-2031 年預測期間複合年增長率為 10.04%。全球原位雜交市場充滿活力,前景廣闊,擁有強大的產品和有利的市場策略。原位雜交市場的推動因素包括癌症患者和遺傳疾病盛行率的增加、原位雜交技術在研發中的使用案例的增加以及分子生物學和基因組學的進步。
原位雜交技術在癌症等疾病的診斷和治療中的有效性已得到證實,並已被醫療保健專業人員廣泛採用。近年來,一些研究機構進行了廣泛的研究,以探索原位雜交的潛力。它加強了研發場景,並導致對此類產品的需求顯著成長。因此,全球癌症患者數量的增加是推動需求的主要因素,因為原位雜交技術在檢測癌細胞和基因突變方面非常有效。我是。然而,產品成本高、缺乏熟練的專業人員以及複雜的數據解釋是阻礙全球原位雜交市場成長的因素。
該報告研究了全球原位雜交市場,並按產品類型、技術、探針類型、應用、最終用戶、地區以及參與市場的公司概況提供了市場概述。更多的。
Global in situ hybridization market size was valued at USD 1.64 billion in 2023 and is expected to reach USD 3.53 billion in 2031, with a CAGR of 10.04% for the forecast period between 2024 and 2031F. The global in situ hybridization market is highly dynamic and promising, with a robust product and favorable market tactics. The in-situ hybridization market is expected to be driven by factors such as the increasing prevalence of cancer cases and genetic disorders, the growing use of in-situ hybridization techniques in research and development, and advancements in molecular biology and genomics.
The proven efficacy of in situ hybridization techniques in diagnosing and managing diseases like cancer led to their growing adoption by healthcare professionals. Several research organizations have spent the last few years conducting extensive research to explore possibilities around in situ hybridization. It has enhanced the research and development scenario and led to significant growth in demand for such products. Hence, growing cancer cases across the globe is a major factor driving the demand for in situ hybridization techniques as it is highly efficient in detecting cancerous cells and genetic mutations. However, the high cost associated with products, lack of highly skilled professionals, and interpretation of complicated data are some hindrances in the growth of the global in situ hybridization market.
In May 2023, Bio-Techne announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio with the commercialization of RNAscope multi-omic workflow for the Standard BioTools Hyperion Imaging System.
Bio-Techne is an international life sciences firm providing innovative tools and bioactive reagents for research and clinical diagnostics. The RNAscope is considered the gold standard for in situ hybridization and is trusted by biotechnological researchers worldwide, with a rapidly growing list of over 8,000 peer-reviewed publications.
In situ hybridization techniques are used in genetic testing for cancers. These techniques help to detect chromosomal changes in patients and help healthcare professionals to identify the type of cancer, based on which the treatment is designed. Due to vast applications of in situ hybridization, techniques in the diagnosis of cancers and other genetic diseases are further driving the demand in the market. Besides cancers, in situ hybridization techniques are extensively utilized to diagnose other indications like infectious, viral, and immunological diseases. The American Society of Cancer estimates that 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Cancer Research UK estimates that there will be 28 million cancer cases per year by 2040. It states that the United Kingdom's incidence is ranked higher than 90% of the world.
The global in situ hybridization market is positively impacted by increased research and development surrounding genome exploration, diagnostic research, and its other healthcare and life sciences applications. Over the past few decades, the human genome project has significantly contributed to the growing body of research concerning genetic explorations and life sciences research. The market is anticipated to rise significantly with the growing acceptance and application of in situ hybridization in diagnostic centers, hospitals, and institutional and academic research projects. To increase their worldwide presence, major companies in the market are pursuing tactics including new launches, mergers and acquisitions, and partnerships.
In February 2023, Molecular Instruments (MI), which is a biotech firm under the umbrella of the California Institute of Technology, launched HCR RNA-CISH. The product is expected to stimulate automated chromogenic in situ hybridization (ISH) workflows that depend on Bio-Techne's RNAscope. According to the company, HCR RNA-CISH kits offer twice the turnaround time and half the cost of any current chromogenic in situ hybridization (CISH) method, while delivering superior performance. HCR RNA-CISH has native support for IHC codetection and is fully compatible with all popular automation platforms.
The fluorescent in situ hybridization (FISH) technique finds a vast range of usage in the diagnosis of congenital disorders like Down's syndrome and other genetic diseases including cancer detection and identification. The growing application areas of fluorescent in situ hybridization (FISH) and its growing demand due to the rising burden of cancers and other genetic diseases is expected to make the fluorescent in situ hybridization (FISH) segment dominate the in situ hybridization market. The COVID-19 pandemic significantly boosted in situ hybridization and several research was done on it. For instance, in September 2023, a group of researchers published a protocol in STAR protocol, for the detection of infectious SARS-CoV-2 virus at low levels through in situ hybridization techniques.
North America is anticipated to dominate the market with the highest value share regarding its significant investment in research and development, technical breakthroughs made by major companies, highly developed healthcare infrastructure, and well-established research environment in North American nations like the United States and Canada. The government's actions and initiatives to assist medication development, genetic exploration, and cancer treatment contribute to the market's growth.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of tactics. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, partnerships, product launches, and development of new solutions, to bolster their position in the market.
In October 2023, Ikonisys SA partnered with Biocare Medical to expand the FISH diagnostic product portfolio. Biocare Medical is a leading firm providing immunohistochemistry (IHC) and Fluorescent in situ hybridization (FISH) tools and reagents while Ikonisys SA specializes in early and accurate detection of cancer through its unique fully automated solution for medical diagnostic labs. This partnership focuses on expanding the global distribution of products of Ikonisys SA, especially, the low-volume Ikoniscope20 and high-volume Ikoniscope20max. Earlier, Biocare Medical acquired Empire Genomics to expand its offering to include over 1 million FISH probes.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.